Novartis Oncology Pipeline Has Three Potential Blockbusters In The Offing
Executive Summary
Novartis is aiming to launch a trio of potential blockbuster oncology drugs in the next few years that the firm hopes will erase the memory of several recent high-profile setbacks in multiple therapeutic areas